vTv Therapeutics (VTVT) Cash from Financing Activities (2014 - 2025)

vTv Therapeutics has disclosed Cash from Financing Activities across 12 years of filings, most recently posting -$321000.0 for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at -$321000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $77.4 million (up 47.21% YoY), and the FY2025 annual result was $77.4 million, up 47.21% from the prior year.
• Cash from Financing Activities came in at -$321000.0 for Q4 2025 at vTv Therapeutics, down from $77.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $77.8 million in Q3 2025 to a low of -$321000.0 in Q4 2025.
• The 5-year median for Cash from Financing Activities is $4.4 million (2022), against an average of $11.5 million.
• Peak annual rise in Cash from Financing Activities reached 4711.72% in 2023, while the deepest fall reached 107.69% in 2023.
• vTv Therapeutics' Cash from Financing Activities stood at $266000.0 in 2021, then jumped by 1278.57% to $3.7 million in 2022, then plunged by 107.69% to -$282000.0 in 2023, then surged by 973.4% to $2.5 million in 2024, then tumbled by 113.03% to -$321000.0 in 2025.
• The last three Cash from Financing Activities figures came in at -$321000.0 (Q4 2025), $77.8 million (Q3 2025), and -$42000.0 (Q2 2025), per Business Quant data.